Gilead UK and Ireland Fellowship Programme

The Gilead Fellowship and Medical Grants Programme supports local innovation and best practices in caring for people living with:

  • HIV
  • Cancer
  • Invasive fungal disease
  • Viral hepatitis

Since 2008, the programme has supported over 300 projects, leaving an important legacy in these areas. Applications are invited from healthcare and third sector organisations who are seeking funding for a project that align with the goals of the programme.

For an overview of the Gilead Fellowship Programme, how to apply, and some top tips to help you with your application, take a look at the short video below.



Eligibility Criteria

Applicants are required to demonstrate how their innovative, high-impact project meets the specified, measurable criteria in order to be awarded funding. Successful applicants are expected to communicate progress of their project, and to present their findings at the end of the funding period.

Find out if your project meets any of this year’s criteria by selecting your specialty therapy area below. Projects which fall outside of the scope, but which will add clinical value, or which investigate an area of unmet need can also be submitted and will be reviewed on their merit.

The Fellowship Programme is looking to support projects and initiatives which ultimately lead to an improvement in patient care. Priority will be given to those projects that focus on patients with high-grade lymphomas (e.g., DLBCL, MCL) as well as low-grade lymphomas (e.g., FL, MZL) and acute leukaemias (e.g., adult/paediatric ALL). This can include, but is not limited to, activities such as:

  • Audits or registry reviews assessing patient profiles, disease outcomes and treatment patterns
  • New pathways established for better diagnosis or detection of disease, or prediction or monitoring of safety and efficacy outcomes to treatment
  • New protocols to facilitate improved efficiency in patient care pathways, such as CAR T referrals
  • Investigations into better detection and treatment of special patient populations (for example, blastoid morphological features in MCL and TP53-mutated patients)
  • QoL frameworks to improve monitoring of patient-reported outcome measures or quality of life instruments or educational tools for patients and carers
  • Oncology Nurse focus – novel mechanisms that facilitate improvements in continuity of care for CAR T patients back at their referring treatment centre (RTC)

We encourage you to listen to the following podcast by one of our previous successful awardees of the UK and Ireland Fellowship Programme to learn about their experiences and to find out more about the practical aspects of applying.

Listen now

The application window for CAR T is 28th March – 27th June 2022.

Gilead’s HIV Fellowship Grants Programme 2022 seeks to support initiatives across health care organisations and third sector organisations, that support our ambition of ‘Getting to Zero’:

  • Zero new HIV transmissions;
  • Zero HIV-related stigma;
  • Zero difference in health outcomes and QoL for people living with HIV.

The application window for HIV is 2nd May - 15th July 2022.

We are inviting applications for audit, surveillance or registry projects which aim to assess one or more of the criteria below.

  • Haematology
    • Priority: Impact of antifungal drug-drug interactions with new and existing chemotherapeutics, immunotherapies and novel biologics
    • Impact of newer haematological treatment modalities on the incidence of Invasive Fungal Disease (IFD) in haemato-oncology patients
  • Critical Care
    • Priority: Optimisation and/or use of fungal diagnostics in the ICU to support early diagnosis of IFD and the corresponding impact on treatment course and patient outcomes
    • Antifungal treatment pathways in ICU and how they have been impacted by viral-respiratory associated infections (e.g. COVID, influenza)
  • Other Patient Groups
    • Priority: Incidence and clinical impact of antifungal resistance in patients with IFD
    • Incidence of IFD in new and emerging patient populations
    • Risk and impact of use of prolonged and/or high doses of corticosteroids on the development of invasive fungal disease(s)
    • The additional burden of care of IFD when treating solid organ transplant recipients

Ideally, all of the above criteria should be looked at in association with patient outcomes.

The application window for IFD is 1st March – 27th May 2022.

The Fellowship is looking to support projects and initiatives which ultimately lead to an improvement in patient care. Priority will be given to those projects that focus on patients with breast cancer, though applicants are encouraged to submit projects for other types of solid tumour.

Fellowship funding can be used to support a variety of projects including, but not limited to:

  • Audits or registry reviews assessing patient profiles, disease outcomes and treatment patterns
  • Setting up new infrastructure for better diagnosis or detection of disease, or prediction or monitoring of safety and efficacy outcomes to treatment including increased disease awareness in primary care and amongst members of the public
  • Establishing novel patient support programmes or tools
  • New protocols to facilitate improved efficiency in patient care pathways
  • Frameworks to improve monitoring of patient-reported outcome measures or quality of life instruments or educational tools for patients and careers

Project examples of successful previous applicants include:

  • Creation of real-life videos and animations in translated into multiple local languages outlining a cancer patient’s physical journey through a hospital as well as treatment administration and side effects
  • Creation of a time-lapse video aimed at patients undergoing radiotherapy showing the onset and progress of radiation dermatitis via a diverse range of reactions and skin types, with the intention to enhance patients’ understanding and prevention strategies
  • Development of a hospital-specific breast cancer information website and app intended as a comprehensive resource for patients, translated into multiple local languages and focusing on diagnosis, treatment, follow-up and support, tailored to different breast cancer subtypes

We particularly welcome any project that seeks to reduce inequalities in access to healthcare and outcomes.

The application window for Oncology is 9th May – 30th July 2022.

The Fellowship Programme is looking to support projects and initiatives which ultimately lead to an improvement in patient care within the field of viral hepatitis, with a focus on hepatitis delta virus (HDV). Priority will be given to those projects that focus on the optimisation of the pathways for the diagnosis and management of HDV.

The programme will support proposals that evaluate existing, or implement and evaluate new, innovative initiatives focused on increasing appropriate HDV testing alone or in combination with hepatitis B, with subsequent liver management.

Priority will be given to proposals that demonstrate replicable and scalable potential.

Gilead will not consider proposals that solely request HDV screening costs (including test kits) or proposals that request HDV study drug. Proposals should be drug agnostic.

The application window for viral hepatitis is 16th May – 6th August 2022.

Applicant Q&A and Support Clinic

To aid the application process, we will be hosting two live support clinics with Gilead representatives from each therapy area to provide advice on how to submit a high-quality application. The sessions will include an overview of the application process, the application portal and the supporting materials available.

We would encourage potential applicants to join to ask any questions you may have about the Fellowship Programme (general or therapy area-specific), project eligibility, or the application process.

The next clinic will be held virtually via Zoom on Wednesday 15 June at 12:30 - 13:30 BST.

The clinic will be hosted by Gilead representatives from the CAR T, HIV, oncology and viral hepatitis therapy areas.

To register your interest in attending the first support clinic, please send an email to [email protected] to receive further details and a link to the Zoom meeting invite, subject to suitability. Please include the following information in your email:

  • Your name, role and organisation
  • The Fellowship Programme therapy area you are interested in
  • A brief summary of your project/initiative (2-4 sentences)

We recommend that you read the basic eligibility criteria ahead of registering your interest to attend the clinic. If you are unsure whether your project/initiative is suitable or have any questions at all, please do get in touch and join us.

Contact Us

For more information, general enquiries or questions on a specific application, email us at [email protected] and we will support you with your request.

UK-UNB-1990 May 2022